X
IBRX icon

Xponance’s ImmunityBio IBRX Stock Holding History

Xponance’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Buy
37,774
+9,925
+36% +$75.1K ﹤0.01% 1342
2026
Q1 		$214K Buy
27,849
+4,681
+20% +$32K ﹤0.01% 1444
2025
Q4 		$45.9K Buy
23,168
+5,270
+29% +$11.9K ﹤0.01% 1531
2025
Q3 		$44K Buy
17,898
+112
+0.6% +$288 ﹤0.01% 1496
2025
Q2 		$47K Buy
17,786
+6,765
+61% +$18.2K ﹤0.01% 1462
2025
Q1 		$33.2K Buy
+11,021
New +$33.4K ﹤0.01% 1409

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Xponance's IBRX Position: Q2 2026 in Review

Xponance increased its ImmunityBio (IBRX) stake by 36% in Q2 2026, buying an estimated $75.1K and bringing the position to 37,774 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #1342.

Xponance first reported a position in IBRX in Q1 2025 and has held it in 6 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Xponance held 37,774 shares of ImmunityBio worth $331K as of Q2 2026.
  • Xponance bought 9,925 ImmunityBio shares in Q2 2026, an estimated $75.1K.
  • ImmunityBio made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1342 holding.
  • Xponance first reported a position in ImmunityBio in Q1 2025 and has held it in 6 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.